Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

When Albert Bourla became CEO of Pfizer in 2019, just before the pandemic, he wanted to make Pfizer’s medicines more affordable to more patients. But COVID-19 delayed those plans when Bourla decided ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Pfizer is gearing up for a major push into the obesity drug market, drawing parallels to its success with Viagra. Despite ...

President Trump, during an Oval Office event Tuesday, called out Albert Bourla, the CEO of Pfizer, for overcharging Americans for prescription drugs. "The United States has just 4% of the world’s ...

WASHINGTON -- Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals ...

Pfizer (PFE) CEO Albert Bourla said he's learned to work with some unlikely allies — even those who once questioned the very foundation of his business. "Clearly, that was not going to be my choice ...